Daiichi Sankyo sells Pennsylvania plant to Sharp Packaging
Daiichi Sankyo Inc.has sold its pharmaceutical packaging plant in Bethlehem, Pennsylvania to Sharp Packaging Services, a division of UDG Healthcare. Read More »
Daiichi Sankyo Inc.has sold its pharmaceutical packaging plant in Bethlehem, Pennsylvania to Sharp Packaging Services, a division of UDG Healthcare. Read More »
Daiichi Sankyo Inc. recently announced the enrollment of the first person for its Eliminate-AF study. Read More »
Bracco Imaging has invested in PHS Technologies Group to solidify Bracco's role in the industry and increase the scope of its portfolio software applications related to dose management. Read More »
Popularly known for its ability to enhance facial appearance cosmetically, Botox is now under scrutiny for its possible application for treating major depressive disorder, based on data from a study undertaken by Allergan. Read More »
Incyte Corp. and Merck have initiated a clinical development program that will examine the possibility of combining epacadostat, Incyte’s investigational oral selective IDO1 enzyme inhibitor, with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with metastatic melanoma, non-small cell lung cancer (NSCLC), bladder cancer, renal cell carcinoma (RCC), and squamous cell carcinoma of the head and neck (SCCHN). Read More »
Merck KGaA has signed an agreement with U.K.-based research and development firm Avillion for an investigative, branded pharmaceutical product designed to address plaque psoriasis, with Avillion’s financial support. Read More »
Allergan PLC and Parateks Pharmaceuticals' Phase 3 trials of sarecycline met their 12-week primary efficacy endpoints. Read More »
Restasis MultiDose will now be available and approved by the U.S. Food and Drug Administration for help treating patients with a type of Chronic Dry Eye by helping them make more of their own tears. Read More »
The U.S. Food and Drug Administration has approved Allergan PLC’s Juvéderm Vollure XC for use correcting moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults over 21. Read More »
Sanofi Healthcare, the company behind Xyzal Allergy 24HR, recently announced the results of an allergy-related social experiment involving 160 participants who wore wearable devices for 30 days to track sleep and activity. Read More »
Allergan and Editas Medicine have entered a strategic research and development alliance that gives Allergan exclusive access and the option to license up to five of Editas Medicine’s genome-editing ocular programs. Read More »
The U.S. Food and Drug Administration has accepted Allergan PLC's filing of a supplemental New Drug Application based on new clinical data that would allow the company to list maintenance on its product label for VRAYLAR (cariprazine), a drug used to treat adults with schizophrenia. Read More »
Pernix Therapeutics Holdings Inc. recently announced that it has been given positive feedback on its litigation in regards to the proposed generic version of Zohydro ER with Actavis Laboratories FL Inc. Read More »
Following a precautionary hold on the dosing of an FAAH inhibitor, Janssen has again begun its clinical research of this investigational medication in two Phase 2 studies. Read More »
Sandoz, a Novartis division, has released data for its proposed biosimilar adalimumab (GP2017). Read More »
Janssen Research & Development LLC (Janssen) recently announced findings from two Phase 3 studies reporting the efficacy and safety of guselkumab in the treatment of adults with moderate to severe plaque psoriasis. Read More »
The U.S. Food and Drug Administration recently reclassified Class I devices, which are antigen-based rapid influenza antigen detection systems that are meant to detect the virus from clinical specimens, to Class II devices that are subject to special controls, according to PRNewswire. Read More »
Palatin Technologies Inc. has closed its license agreement with AMAG Pharmaceuticals Inc. for the development of Rekynda in North America. Read More »
The FDA issued a complete response letter in response to Daiichi Sankyo's new drug application regarding CL-108, a drug used in treating and managing pain. Read More »
Allergan has made a substantial donation to the American Association for the Study of Liver Diseases Foundation, becoming part of AASLD’s Founder’s Society. Read More »